EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV-LPD). PCR was performed prior to and after transplantation. An EBV-VL Ͼ300 copies/g DNA was chosen as the threshold for risk of developing an EBV-LPD. Two hundred and fifty-eight EBV-VL measures were evaluable. Five patients (5.9%) developed an EBV-LPD. All had an elevated EBV DNA peak level before EBV-LPD. Fifteen out of 80 recipients (18.7%) without EBV-LPD had EBV levels over 300 copies/g DNA at least once during the follow-up. Overall, the manifestation of at least one EBV-VL over 300 copies/g DNA during the entire follow-up demonstrated a sensitivity, specificity, positive and negative predictive value for the diagnosis of EBV-LPD of 100%, 81%, 25% and 100%, respectively. In patients without EBV-LPD, HLA incompatibility, grade уII acute GVHD and use of an unmanipulated graft were significantly associated with an EBV-VL Ͼ300 copies/g DNA. This strategy appears sensitive for the diagnosis of EBV-LPD but its positive predictive value has to be improved in order to guide pre-emptive therapy.
(EBV-LPD) is a relatively infrequent but often rapidly fatal complication of hematopoietic stem cell transplantation (SCT) which results from uncontrolled transformation of latently infected B lymphocytes into lymphoblastoid cells, generally of donor origin. [1] [2] [3] [4] The clinical spectrum of EBV-LPD varies from an infectious mononucleosis-like syndrome to aggressive disseminated disease, and from a polyclonal disorder to monoclonal malignant lymphoproliferation. 5 Several risk factors for the development of posttransplantation EBV-LPD, most of them inducing profound T cell immunosuppression in the host, have been reported: donor-recipient HLA disparity, T cell depletion of the graft, severity of acute graft-versus-host disease (aGVHD), use of intensive T cell-targeted immunosuppressive regimens, primary immune deficiency disease, and primary EBV infection following transplantation. [6] [7] [8] [9] [10] [11] Because clinical signs occur late, are non-specific and treatment is generally unsuccessful in patients with aggressive disease, the identification of patients at high-risk of developing EBV-LPD could possibly allow prophylactic or early therapeutic intervention by B cell-specific monoclonal antibodies or adoptive transfer of EBV-specific cytotoxic T lymphocytes. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Using quantitative PCR, previous studies in both solid organ and hematopoietic stem cell transplantation have shown that the median number of EBV copies in peripheral blood mononuclear cells (PBMC) is higher in patients who have received a SCT than in healthy individuals and the onset of EBV-LPD is usually preceded by a further increase in EBV viral load (EBV-VL). [23] [24] [25] [26] [27] Nevertheless, the kinetics of EBV-VL after hematopoietic SCT has yet to be analyzed in large studies. We therefore lack a definition of the EBV-VL threshold which could pinpoint the risk of EBV-LPD and thus set in motion pre-emptive or early anti-EBV-LPD therapy. The purpose of this prospective study was to follow, using semi-quantitative PCR, the kinetics of EBV DNA levels in PBMC after transplantation in patients at low and high risk for EBV-LPD, to identify risk factors which induce a high virus burden, and to determine the Bone Marrow Transplantation sensibility, specificity, and predictability of the method in the diagnosis of EBV-LPD.
Patients and methods

Patients
Ninety-one consecutive SCT were performed from October 1995 to May 1998 in three French transplant units. Patient and transplantation characteristics are summarized in Table 1 . Briefly, 44 patients received an HLA genoidentical SCT and 47 an HLA non-genoidentical SCT (HLAmatched or mismatched unrelated transplant or HLA-mismatched family transplant). Forty-four patients who received an HLA non-genoidentical graft received antithymocyte globulin (ATG) prior to, and for 11 of them For the viral analysis, six SCT were further excluded for insufficient virological data. b Fractionated TBI at a total dose of 12 Gy in all patients but one who received a single 7.5 Gy dose. c A busulfan-based preparative regimen was used in 45 transplantations. The four patients with aplastic anemia received cyclophosphamide (CY) ± antithymocyte globulin or 5 Gy TAI + CY. d Cumulative dose for rabbit ATG: 2.5-10 mg/kg, cumulative dose for equine ATG: 12.5-20 mg/kg. e Anti-LFA1 + anti-CD2 monoclonal antibodies. TBI = total body irradiation; TAI = thoracoabdominal irradiation; GVHD = graft-versus-host disease; CsA = cyclosporin A; MTX = methotrexate.
immediately after transplantation (days 0 and +1). The combination of cyclosporine A and methotrexate (CsA + MTX) was the regimen most frequently used as GVHD prophylaxis in HLA genoidentical transplant recipients. The marrow graft was lymphocyte depleted (elutriation ± CD34-positive selection or CD34-positive selection ± CD2/CD7/CD19-negative selection) in 11 HLA non-genoidentical transplants, resulting in a median number of CD3-positive cells equal to 1.69 × 10 The remaining HLA non-genoidentical transplant recipients received CsA ± MTX ± corticosteroids. Acute GVHD was graded according to Glucksberg's criteria. 28 Patients with grade у II aGVHD were treated with corticosteroids (methylprednisolone 2-5 mg/kg per day) as first-line treatment. Refractory disease was treated with high-dose corticosteroids or ATG or anti-CD25 monoclonal antibodies. 29 
Diagnosis of EBV-LPD
Two situations were considered for the clinical diagnosis of EBV-LPD: (1) tumor lymphoproliferation, essentially degree of lymphadenopathy or hepatosplenomegaly, (2) unexplained fever without any tumor accompanied by a rise in peripheral blood B lymphocytes (CD19 + cells) and the occurrence of monoclonal or oligoclonal gammopathy. When biopsy specimens were available, we studied the classical morphologic and immunologic characterization, and the immunoglobulin gene rearrangement by Southern blot. The presence of EBV within the biopsy was assessed either by immunohistochemistry detection of EBV-latent membrane-protein 1 (LMP1) or detection of Epstein-Barrencoded RNA (EBER) by in situ hybrization or by EBV PCR according to the routinely used methods of the three centers.
Semi-quantitative PCR
Samples of 5 to 15 ml of blood were taken for analysis prior to and on days +30, +60 and +90 after transplantation. PBMC were collected after Ficoll-Hypaque separation and conserved at −80°C until the PCR assay. PCR analyses were carried out in one center that routinely carried out EBV PCR analysis and performed without the knowledge of the clinical status of the patients. The semi-quantitative EBV PCR strategy was adapted from the study of Rooney et al 26 and has already been published. [30] [31] [32] Briefly, after a phenol chloroform extraction, the PCR assay amplified a 120-bp fragment within the only BamHI C region of EBV. After electrophoresis, the DNA fragments were transferred to nylon membranes and hybridized to a 32 P-ATP-labelled BamHI C-specific DNA probe. Using dilutions of the EBVinfected Namalwa cells which are known to have one to two copies of integrated EBV genome, the sensitivity of the PCR reaction was determined to be three copies of the EBV genome per 1 g of DNA, corresponding approximately to 150 000 PBMC. Semi-quantitative EBV PCR was estimated after visual comparison of the autoradiographic signals of amplified BamHI C products to the sig-nals obtained with serial 10-fold dilutions of the Namalwa cell line in the EBV-negative BJAB cell line. Dilutions of Namalwa cells in BJAB cells were made to obtain 1 g to 10 pg of DNA corresponding to a range of three EBV copies (1.5 Namalwa cell in 150 0000 BJAB cells) to 300 000 copies (150 000 Namalwa cells + 0 BJAB cell). This method, based on external standard and visual comparison, has been successfully used in other studies in the transplantation setting but cannot give an absolute value. 26, 27 The number of copies for each sample was estimated to be within six ranges: 3-30, 30-300, 300-3000, 3000-30 000 and over 30 000 copies/g DNA. As expected with the BamHI C PCR EBV, more than 100 seropositive healthy carriers showed a negative result in PBMC most of the time or were rarely found to be at 3-30 or 30-300 copies/g DNA (data not shown), a result in agreement with the estimated number of EBV-infected lymphocytes during longterm latent infection in EBV seropositive immunocompetent individuals (1 to 5 in 10 6 PBMC). 33 We have carried out intra-and inter-assay experiments on 30 randomly selected negative and 30 positive specimens (10 samples with a viral load at 3-30 copies/g, 10 samples with a viral load at 30-300 copies/g and 10 samples with a viral load Ͼ300 copies/g DNA). All these samples have been tested blindly in duplicate in the same assay for intra-assay variability and retested during another PCR experiment for interassay variability. All the negative samples tested repeatedly negative. For the positive samples, intra-assay and interassay variability was always below one log 10. Because studies with similar semi-quantitative PCR have established early therapy with EBV-specific cytotoxic cells in SCT patients when EBV-VL exceeded 150 or 300 copies in 1 g of DNA, the range 300-3000 copies/g DNA was chosen as the threshold for a risk of developing an EBV-LPD.
18,19
Statistical analysis
The sensitivity, specificity, positive predictive value (PPV), and negative predictive values (NPV) of the EBV-VL equal to 300-3000 copies/g DNA for the diagnosis of EBV-VL were determined with the standard formula by comparing the total number of EBV-VL measures equal to or greater than 300-3000 copies/g DNA and the total number of EBV-VL measures less than 300-3000 copies/g DNA in patients who developed EBV-LPD and in those who did not. In patients who did not develop EBV-LPD, the chisquare test and regression logistic analysis were performed to correlate EBV-VL with age, sex, HLA incompatibility, grade уII acute GVHD, and use of an unmanipulated or lymphocyte-depleted graft.
Results
Of the initial 91 SCT included in the study, 14 patients died during the first 90 days after transplantation (median follow-up 314 days; range 26-867 days). Six patients (four had received an HLA genoidentical graft and two an HLA non-genoidentical graft) had only one sample of EBV-VL collected before transplantation and none after transplant (because death occurred before day +30 in two patients, Bone Marrow Transplantation and because it was overlooked in four patients) and were therefore excluded from viral analysis (none of the patients excluded developed EBV-LPD during clinical follow-up). Thus, for the final viral analysis, 85 SCT were included with a median follow-up of 306 days (26-867 days) and 258 measures of EBV-VL were carried out, representing 75.9% of all the programed tests and a mean of three measures per SCT. Of the 258 measures, an EBV-VL higher than 300 copies/g DNA was observed six times out of 66 (9.1%) before transplantation and 28 times out of 192 (14.6%) after transplantation.
Five patients (5.9%) developed EBV-LPD: four during the first 90 days and one at day +180 (see below). All five patients had an EBV-VL higher than 300 copies/g DNA before the diagnosis, whereas this level was detected at least once within the post-transplantation follow-up in 15 of 80 patients (19%) without EBV-LPD (Table 2 ). Among them were four out of 40 (10%) and 11 out of 40 (27.5%) recipients of HLA genoidentical and non-genoidentical hematopoietic stem cells, respectively. Overall, the demonstration of at least one EBV-VL Ͼ300 copies/g DNA during the entire follow-up demonstrated a sensitivity, specificity, positive predictive value, and negative predictive value for the diagnosis of EBV-LPD of 100%, 81%, 25% and 100%, respectively.
In all five patients with EBV-LPD, EBV DNA levels increased to more than 300 copies/g DNA at day +60 whereas this level was continually in the normal range at day +30. Four patients (UPN 1, 2, 3 and 4) developed EBV-LPD during this study period, at days + 90, +75, +61 and +66, respectively, and the last patient (UPN5) had EBV-LPD on day +180 (Table 3 ). All five patients received an HLA non-genoidentical transplant, with lymphocyte depletion of the graft in two (UPN 1 and 4) . Pre-transplantation EBV serology was positive in UPN 2, 4 and 5 and negative in UPN 1 and 3. Donors were EBV seropositive for all except one (UPN 5).
UPN 1 had disseminated disease with fever, generalized lymphadenopathy, as well as bone marrow and cerebrospinal fluid involvement confirmed by the detection of blasts and presence of EBV DNA in bone marrow and cerebrospinal fluid. Pathological and virological analysis revealed EBV-positive polymorphic post-transplantation Table 2 Results of EBV DNA-viral load in peripheral blood mononuclear cells of transplant recipients D +60 300-3000 D+90 300-3000 ATG = antithymocyte globulin; aGVHD = acute graft-versus-host disease; DLI = donor lymphocytes injection; D+75 = day 75 post transplantation; ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; NHL = non-Hodgkin's lymphoma. a EBV DNA levels = copies/g DNA.
lymphoproliferative disease which was polyclonal from donor origin. At the time of diagnosis (day +90), the EBV-VL was very high (Ͼ30 000 copies/g DNA). Donor T lymphocytes (5 × 10 5 CD3/kg) were infused on days +94 and +107 after transplantation using the strategy used by Papadopoulos et al. 12 The patient deteriorated rapidly, with idiopathic respiratory distress, probably related to donor lymphocyte infusion and died on day +109. The EBV-VL could not be checked after the infusion of T lymphocytes, due to the rapidly fatal course of the patient.
In UPN 2, EBV-LPD was characterized by localized disease with cervical lymphadenopathy. Biopsy showed EBVpositive immunoblastic lymphoma which was found to be monoclonal, of donor origin. This patient received anti-CD20 monoclonal antibodies, (rituximab 375 mg/m 2 ) on days +75 and +80. [20] [21] [22] She died on day +87 after transplantation from refractory aGVHD. Again, EBV-VL could not be checked after the infusion of monoclonal antibodies.
The other two patients (UPN 3 and 4) both developed persistent unexplained fever associated with rise in peripheral blood B lymphocytes (UPN 3: 2% CD19
+ peripheral lymphocytes at day +52, 51% at day +60; UPN 4: 0% CD19
+ peripheral lymphocytes at day + 40, 17% at day +55, 35% at day +60) and a monoclonal gammopathy at days +61 and +66 (Table 3) , respectively. Clinical evaluation and total computerized tomography revealed no tumor proliferation. In patient UPN 3, the EBV-VL rose from negative at day −10 and day +30 to Ͼ3000 copies at day +60. UPN 3 received anti-IL6 monoclonal antibodies intravenously (anti-IL6 BE8 antibodies; Dr Wijdenes, Besançon, France), 0.4 mg/kg per day on day +62 for 14 days, followed by infusion of donor T lymphocytes (CD3 + cells: 5 × 10 5 /kg). EBV-VL was still high at day +80. The patient died on day +87 from idiopathic interstitial pneumonitis. Post-mortem examination revealed diffuse alveolar damage and EBV detection within the lungs was negative. Because of clinical symptoms and a rising EBV-VL between day +30 and day +60, UPN 4 who had received a transplant of purged peripheral blood stem cells from a family haploidentical donor, received anti-CD20 monoclonal antibodies from day +70 (rituximab: 375 mg/m 2 once a week for 4 weeks). He had an objective response after the second infusion: resolution of fever, return of peripheral blood lymphocytes to a normal percentage (1%), and disappearance of monoclonal gammopathy. Concomitantly, EBV-VL decreased to 3-30 copies/g DNA at day +90. He died on day +112 from a severe undocumented infection.
The last patient (UPN 5) developed late cerebral EBV-LPD after the study period (Table 3) . She received a transplant of unrelated HLA 2 locus incompatible cord blood stem cells from an EBV seronegative donor, along with pre-transplant lymphoglobulin. Grade II aGVHD occurred on day +33 and resolved with methylprednisolone. Around day +180 she developed unexplained fever and progressive neurological disturbances including seizures, hypotonia, right hemiparesis and dysphagia. Contrast-enhanced T2-weighted magnetic resonance imaging revealed diffuse lesions of the two parieto-temporal and occipital lobes and the brain stem. A high level of EBV DNA was detected by PCR in the cerebrospinal fluid. The patient died on day +216 from neurological complications. Post-mortem biopsies showed encephalic and meningeal immunoblastic large cell lymphoma, CD20
+ of donor origin, associated with discrete infiltration of the spleen. Most cells expressed EBV-encoded LMP1 but the origin of the EBV could not be determined. EBV-VL was Ͼ300 copies/g DNA at days +60 and +90 and was never checked thereafter. This case has been described elsewhere and is, to our knowledge, the first case reported after cord blood SCT. 34 Overall, 178 samples were collected after transplantation in 80 patients without EBV-LPD. Analysis of EBV-VL kinetics after transplant showed that EBV-VL remained stable in recipients of an HLA genoidentical graft at successive screening times after transplant. In contrast, recipients of HLA non-genoidentical grafts showed a significantly higher frequency of positive results at days +60 and +90 compared with day +30 (P = 0.03) ( Table 4) . Nevertheless, a very high EBV-VL of more than 30 000 copies/g DNA was never observed in patients without EBV-LPD. Seven donor/recipients pairs were EBV seronegative before the transplantation. No EBV-LPD was observed in this group of patients. The value of the EBV-VL was always less than 300 copies/g DNA in the 12 measures performed after transplantation.
On the 178 samples, predisposing factors for post-transplantation levels of EBV-VL DNA Ͼ300 copies/g DNA were examined. Statistically significant correlations were found between elevated EBV DNA levels and HLA incompatibility of the graft (P Ͻ 0.01), use of an unmanipulated graft (P Ͻ 0.01), and grade уII aGVHD (P Ͻ 0.01) but not with patient age, recipient gender, and patient pretransplantation EBV serology (Table 5) . Logistic regression analysis showed that HLA incompatibility of the graft and grade уII aGVHD were independently correlated with high EBV-VL with an odds ratio of 5 (95%CI: 1.5-16.4) and 3.4 (95%CI: 1.2-9.7)
Discussion
The poor prognosis for patients developing overt EBV-LPD has led several authors to screen high-risk patients before the onset of clinical symptoms, hypothesizing that prophy- laxis, pre-emptive, or early therapy may improve the outcome of this complication. [12] [13] [14] [15] [16] [17] [18] [19] An increase in the EBV viral burden by measuring EBV DNA levels in the blood has been considered as an early marker of EBV-LPD in previous studies and has been proposed as a guide of anti-EBV-LPD therapy. [23] [24] [25] [26] [27] In this report, we prospectively used a semi-quantitative PCR measure of EBV DNA in PBMC at different times after transplantation in 85 SCT recipients in order to assess the ability of this measure to predict the development of EBV-LPD, and to characterize the kinetics of EBV DNA levels in both low-and high-risk patients for EBV-LPD. The cut off of 300-3000 copies/g DNA was chosen as a marker of risk for the emergence or the presence of EBV-LPD because it corresponded very closely to the previously published estimated threshold in PBMC for the risk of EBV-LPD. 26, 27, 33 Five patients out of 85 (5.9%) developed EBV-LPD and in all five, EBV-VL rose from a negative or low VL (Ͻ3 copies or 3-30 copies/g DNA) to an EBV-VL of 300 copies or more before or at the time of clinical EBV-LPD symptoms. In the two patients with tumor lymphoproliferation, EBV DNA levels were increased from day +60, 15 days and 1 month before clinical symptoms, respectively. These two patients were rapidly treated after the diagnosis of EBV-LPD, but died too early after initiation of therapy to evaluate tumor regression: UPN 1 died from idiopathic interstitial pneumonitis, a well-known complication of DLI, 12 whereas UPN 2 died from multiorgan failure in the context of steroid-resistant aGVHD. Moreover, in two cases, non-specific clinical symptoms associated with elevated EBV-VL levels prompted the clinicians to begin an anti-EBV-LPD-specific therapy and, in one case (UPN 4), clinical response to treatment (anti-CD20 antibody) was associated, as described in the literature, with a decrease in EBV-VL. 22 ,35 DLI-related acute respiratory distress was probably the cause of death in UPN 3, which occurred before any evaluation of clinical response to treatment. The last patient (UPN5) developed a late disseminated EBV-LPD, 6 months after transplantation and a high EBV-VL was observed at day +60 and day +90. These results from a large cohort of patients tended to confirm the usefulness of the EBV-VL follow-up in SCT. Nevertheless, 15 patients out of 80 (19%) without EBV-LPD were found to have high EBV-VL (Ͼ300 copies/g DNA ) during follow-up and the positive predictive value of this test for developing EBV-LPD based on having Ͼ300 copies/g DNA was low. Similar results have already been reported in previous studies using similar semi-quantitative EBV PCR in PBMC, where increases in viral load were not always associated with further development of EBV-LPD and, conversely, some EBV-LPD cases were not accompanied by an increase in the EBV-VL. [24] [25] [26] [27] In a recent study by Allen et al, 36 the positive and negative predictive value of the semi-quantitative EBV PCR were 28 and 95%, respectively. In the study conducted by Lucas et al, 27 five of seven patients with EBV-LPD had levels of EBV DNA Ͼ40 000 copies/g DNA and two of the 34 patients without EBV-LPD had levels of EBV DNA Ͼ40 000 copies/g DNA, giving the positive and negative predictive value for this test as 71% and 94%, respectively. In our study, if the EBV-VL threshold had been placed at 3000-30 000 copies/g DNA or greater, the sensitivity of the test in detecting EBV-LPD would have been too low (40%), with a weak increase in the PPV (40%). The weak positive predictive value did not seem to be entirely related to the semiquantitative as compared with more accurate quantitative or real time PCR, [37] [38] [39] [40] since in another study we demonstrated a good correlation between the semi-quantitative method and real time quantitative PCR. 41 In fact, from our study and others published, it seems that a closer followup of the viral burden between day +30 and day +90 and the demonstration of a fast increase in viral burden is probably a better predictor of disease onset than is an elevated absolute value of viral burden. Recently, Stevens et al, 42 using a weekly quantitative PCR in unfractionated whole blood from patients with lung transplants, found that 78% of the samples from patients with EBV-LPD vs 3.4% of the samples from patients without EBV-LPD were superior to a cut-off value similar to our cut-off value.
To circumvent the apparent lack of specificity of EBV DNA detection by semi-quantitative PCR in PBMC, some authors have used detection of EBV DNA in an acellular specimen such as serum hypothesizing that the presence of EBV DNA in serum would differentiate patients with EBV-LPD from those with EBV reactivation as a result of immunosuppression. 37, 43, 44 Since the end of this study, we have tested 109 plasma specimens collected at the same time as PBMC and preserved at −80°C with the same EBV PCR protocol. Of the 94 plasma specimens corresponding to the 94 cellular VL Ͻ300 copies/g DNA, 90 were PCR negative and four were weakly positive (3-30 copies). Of the 15 plasma specimens corresponding to the 15 cellular VL Ͼ300 copies/g DNA, only two plasmas were Ͼ300 copies. In this retrospective experiment, the measurement of VL in plasma did not improve the predictive value of the test as compared with the cellular viral load. This result has been confirmed in two recently published studies which demonstrated the lack of use of plasma or serum VL measurements even with quantitative PCR or real time PCR. 42, 45 The post-transplantation kinetics of EBV DNA levels show undetectable viral DNA levels during the first month after transplantation, probably because of the limited number of circulating B lymphocytes. Significant fluctuations of post-transplantation EBV-VL were seen thereafter in HLA non-genoidentical graft recipients as opposed to HLA genoidentical graft recipients who showed no major posttransplantation variation. The enhancement of viral load observed after day +30 in HLA non-genoidentical graft recipients may result from the rapid growth of EBVtransformed B cell clones present in the graft when EBVspecific cytotoxic T cells are at their nadir. 46 In patients without EBV-LPD, donor-recipient HLA disparity and grade уII aGVHD, both depressing cellular immunity, correlated independently with high EBV-VL. Similarly, an unmanipulated graft rather than lymphocyte depletion was associated with elevated EBV DNA levels. In 10 out of 11 recipients of lymphocyte-depleted grafts who did not develop EBV-LPD, EVB-VL was always low, whereas it was high in 16/61 measures performed in recipients of unmanipulated graft (P Ͻ 0.01). Both B and T cell depletion used in our study may partially explain this unexpected result. In fact, previous groups have demonstrated that the magnitude of EBV-LPD risk depends on the lymphocyte depletion method. For example, methods depleting both T and B lymphocytes (lectin agglutinin, Campath-1, elutriation, CD34
+ selection, addition of an anti-B monoclonal antibody to T cell depletion regimen) generally resulted in a lower incidence of lymphomas than did techniques selectively depleting T cells (OKT3 monoclonal antibody). 6, 11, [47] [48] [49] Similarly, the nature of T cell antibodies used to prevent or treat graft failure and/or aGVHD may affect EBV-LPD incidence, possibly reflecting differences in their capacity to suppress or indirectly stimulate B cell proliferation. 50 In conclusion, interindividual susceptibility to EBV-LPD is not totally understood and is not totally explained by EBV-VL. A discrepancy between viral burden and level of cellular immunity to EBV probably exists, and/or infection by other more tumorigenic viral strains may also play a role. 51, 52 Detection by semi-quantitative PCR of an EBV VL over 300 copies/g of DNA in PBMC appears to be a sensitive and relatively specific method for diagnosing EBV-LPD in hematopoietic stem cell transplant recipients, but the positive predictive value of this test in patients at risk of EBV-LPD is low. Thus, efforts to standardize the measure of EBV-VL should be continued and the viral criteria sufficiently specific to justify a prophylactic or preemptive strategy in patients at high risk of EBV-LPD must be refined further.
